Standard Versus Higher Intensity Anticoagulation for Patients With Mechanical Aortic Valve Replacement and Additional Risk Factors for Thromboembolism.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 11 2021
Historique:
received: 21 04 2021
revised: 03 08 2021
accepted: 09 08 2021
entrez: 17 10 2021
pubmed: 18 10 2021
medline: 25 11 2021
Statut: ppublish

Résumé

Current guidelines recommend targeting an international normalized ratio (INR) of 2.5 to 3.5 for patients with mechanical aortic valve replacement (AVR) and additional risk factors for thromboembolic events. Available literature supporting the higher intensity (INR) goal is lacking. We aimed to evaluate the association of standard and higher intensity anticoagulation on outcomes in this patient population. The Michigan Anticoagulation Quality Improvement Initiative database was used to identify patients with mechanical AVR and at least one additional risk factor. Patients were classified into 2 groups based on INR goal: standard-intensity (INR goal 2.5) or higher-intensity (INR goal 3.0). Cox-proportional hazard model was used to calculate adjusted hazard ratios. One hundred and forty-six patients were identified of whom 110 (75.3%) received standard-intensity anticoagulation and 36 (24.7%) received higher intensity anticoagulation. Standard-intensity patients were older and more likely to be on aspirin. Atrial fibrillation was the most common additional risk factor for inclusion. The primary outcome of thromboembolic events, bleeding, or all-cause death was 13.9 and 19.5/100-person-years in the standard-intensity and higher intensity groups, respectively (adjusted HR 2.58, 95% confidence interval 1.28 to 5.18). Higher-intensity anticoagulation was significantly associated with any bleeding (adjusted HR 2.52, 95% confidence interval 1.27 to 5.00) and there were few thromboembolic events across both groups (5 events total). These results challenge current guideline recommendations for anticoagulation management of mechanical AVR in patients with additional risk factors.

Identifiants

pubmed: 34656311
pii: S0002-9149(21)00782-7
doi: 10.1016/j.amjcard.2021.08.023
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100-106

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Sarah Hanigan (S)

Department of Pharmacy, Michigan Medicine, Ann Arbor, Michigan; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan. Electronic address: hanigan@med.umich.edu.

Xiaowen Kong (X)

Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan.

Brian Haymart (B)

Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan.

Eva Kline-Rogers (E)

Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan.

Scott Kaatz (S)

Division of Hospital Medicine, Henry Ford Hospital, Detroit, Michigan.

Gregory Krol (G)

Division of Hospital Medicine, Henry Ford Hospital, Detroit, Michigan.

Vinay Shah (V)

Division of Hospital Medicine, Henry Ford Hospital, Detroit, Michigan.

Mona A Ali (MA)

Department of Heart and Vascular Services, Beaumont Hospital, Royal Oak, Michigan.

Steve Almany (S)

Department of Internal Medicine, Beaumont Health, Oakland University William Beaumont School of Medicine, Rochester, Michigan.

Jay Kozlowski (J)

Department of Cardiovascular Medicine, Huron Valley Sinai Hospital, Commerce Township, Michigan.

James Froehlich (J)

Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan.

Geoffrey Barnes (G)

Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Institute of Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH